Piedmont Research Partners, LLC

Fort Mill, South Carolina 29707-4514

2 studies enrolling now · 12 studies all time

What they study most

Atherosclerotic Cardiovascular Disease, Atrial Fibrillation, COPD, Cardiovascular Disease and Lipoprotein(a), Cardiovascular Diseases, Cardiovascular Risk, Chronic Kidney Disease, Chronic Kidney Disease (CKD), Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, Type 2, Gout

Studies at this site

• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Recruiting now
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation — Completed
• A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD — Running, not enrolling
• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition — Completed
• A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke — Stopped early
• A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES) — Completed
• Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease — Running, not enrolling
• Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis — Stopped early
• A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment — Stopped early
• Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD — Completed